Characterisation of the barrier caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystine-knot microproteins

Amino Acids

Volumn 35, Issue 1, 2008, Pages 195-200

  Werle, M ^a,d   Kolmar, H ^b   Albrecht, R ^a   Bernkop Schnurch A ^c  

^a Thiomatrix Forschungs und Beratungs GmbH   (Austria)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d Institute of Pharmacy   (Austria)

Author keywords

CKM; Cystine knot microproteins; Enzymatic degradation; Oral delivery

Indexed keywords

CHYMOTRYPSIN; CYSTINE; ELASTASE; ENZYME INHIBITOR; INSULIN; PEPSIN A; PEPTIDE; PROTEINASE; RECEPTOR BLOCKING AGENT; SE ET TP 020; SE MC TR 020; TRYPSIN;

ARTICLE; CONTROLLED STUDY; CYSTINE KNOT MOTIF; ENZYME RELEASE; GASTROINTESTINAL TRACT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; STOMACH JUICE;

ANIMALS; GASTRIC JUICE; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINAL SECRETIONS; PEPTIDE HYDROLASES; SWINE; TIME FACTORS;

SUS;

EID: 44849084819     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-007-0569-1     Document Type: Article

References (18)

1. Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Le Nguyen D, Sommerhoff CP, Diederichsen U, Kolmar H (2005) Trypsin inhibition by macrocyclic and open-chain variants of the squash inhibitor MCoTI-II. Biol Chem 386: 1301-1306
2. Bernkop-Schnürch A (1998) The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Rel 52: 1-16
3. Bernkop-Schnürch A, Fragner R (1996) Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration. Pharm Sci 2: 361-363
4. Christmann A, Walter K, Wentzel A, Kratzner R, Kolmar H (1999) The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Eng 12: 797-806
5. Colgrave ML, Craik DJ (2004) Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43: 5965-5975
6. Craik DJ, Daly NL, Bond T, Waine C (1999) Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol 294: 1327-1336
7. Craik DJ, Daly NL, Waine C (2001) The cystine knot motif in toxins and implications for drug design. Toxicon 39: 43-60
8. Craik DJ, Cemazar M, Daly NL (2006) The cyclotides and related macrocyclic peptides as scaffolds in drug design. Curr Opin Drug Discov Devel 9: 251-260
9. Doggrell SA (2004) Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 13: 875-877
10. Grain L (1973) Isolation of oxytocic peptides from Oldenlandia affinis by solvent extraction of tetraphenylborate complexes and chromatography on sephadex LH-20. Lloydia 36: 207-208
11. Kratzner R, Debreczeni JE, Pape T, Schneider TR, Wentzel A, Kolmar H, Sheldrick GM, Uson I (2005) Structure of Ecballium elaterium trypsin inhibitor II (EETI-II): a rigid molecular scaffold. Acta Crystallogr D Biol Crystallogr 61: 1255-1262
12. Loretz B, F€euro;oger FA, Werle M, Bernkop-Schnürch A (2006) Oral gene delivery: strategies to improve stability of pDNA towards intestinal digestion. J Drug Targ 14: 311-319
13. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS (1994) A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptides. Protein Sci 3: 1833-1839
14. Swarbrick J, Boylan JC (2002) Encyclopedia of pharmaceutical technology, 2nd ed. Marcel Dekker, Inc., New York, p 885
15. Werle M, Schmitz T, Huang H, Wentzel A, Kolmar H, Bernkop-Schnürch A (2006a) The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Targ 14: 137-146
16. Werle M, Samhaber A, Bernkop-Schnürch A (2006b) Degradation of teriparatide by gastro-intestinal proteolytic enzymes. J Drug Targ 14: 109-115
17. Werle M, Bernkop-Schnürch A (2006c) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30: 351-367
18. Woodley JF (1994) Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 11: 61-95